Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Trivalent Influenza Vaccine in T2DM and CKD Patients
NCT06252051Phase 4Completed
- Sponsor
- Universitas Padjadjaran
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trivalent influenza vaccine in influenza, sponsored by Universitas Padjadjaran. Primary endpoints: Influenza-Like Illness Morbidity at 6 months and Antibody Titers at 6 months. Started Jan 2021; status: completed.
02
Drugs
trivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06252051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252051.